Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 4/2015

01.07.2015 | Original Article

Safety and Efficacy of Oral Mifepristone in Pre-induction Cervical Ripening and Induction of Labour in Prolonged Pregnancy

verfasst von: Kanan Yelikar, Sonali Deshpande, Rinku Deshpande, Dipak Lone

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective(S)

To study the safety and efficacy of oral mifepristone in pre-induction cervical ripening and induction of labour in prolonged pregnancy.

Method(S)

This is a single blind randomized control trial. 100 women with prolonged pregnancy beyond 40 weeks and Bishop score <6 were recruited, and randomly allocated into two groups. Women who received Tab. Mifepristone 200 mg orally were assigned in Study Group (n = 50) and who received placebo orally were assigned in Control Group (n = 50) At the end of 24 h, change in the Bishop’s score was assessed and Tab. Misoprostol 25 μg was administered intravaginally every 4 h, maximum 6 doses for induction/augmentation of labour. Analysis regarding safety and efficacy of the drug was done with regards to maternal and perinatal outcome.

Result(S)

Among 100 subjects, 50 received mifepristone and 50 received placebo. Mean induction to delivery interval was 1,907 ± 368.4 min for Study Group versus 2,079 ± 231.6 min for Control Group. The improvement in mean Bishop score was 5.0408 ± 1.90 for Study Group compared with 3.26 ± 1.15 was for Control Group after 24 h. Mean dose of misoprostol in Study Group was 40 ± 27.2, while the same in Control Group was 52 ± 19.46. Eight (16 %) women in Study Group and two (4 %) women in Control Group delivered vaginally within 24 h without any need of augmentation. There were 6 (12 %) cesareans and 2 (4 %) instrumental deliveries in Study Group and 8 (16 %) cesareans and 5 (10 %) instrumental deliveries in the Control Group. There was no statistically significant difference in perinatal outcomes between two groups.

Conclusion(S)

Mifepristone had a modest effect on cervical ripening when given 24 h prior to labour induction and appearing to reduce need for misoprostol compared with placebo.
Literatur
1.
Zurück zum Zitat Heikinheimo O, Kekkonen R, Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003;68(6):421–6.PubMedCrossRef Heikinheimo O, Kekkonen R, Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003;68(6):421–6.PubMedCrossRef
2.
Zurück zum Zitat Gemzell-Danielsson K. a Sujata Lalitkumar. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management reproductive health matters. 2008;16(31 Supplement):162–1726.PubMed Gemzell-Danielsson K. a Sujata Lalitkumar. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management reproductive health matters. 2008;16(31 Supplement):162–1726.PubMed
3.
Zurück zum Zitat Dharani H, James PN. Mifepristone for induction of labour(review). Chochrane Database Syst Rev. 2009; 3, Art. No. CD002865. Dharani H, James PN. Mifepristone for induction of labour(review). Chochrane Database Syst Rev. 2009; 3, Art. No. CD002865.
4.
5.
Zurück zum Zitat Wing DA, Fassett Michael J, Mishell Daniel R. Mifepristone for preinduction cervical ripening beyond 41 weeks’ gestation: a randomized controlled trial. Obstet Gynecol. 2000;96:543–8.PubMedCrossRef Wing DA, Fassett Michael J, Mishell Daniel R. Mifepristone for preinduction cervical ripening beyond 41 weeks’ gestation: a randomized controlled trial. Obstet Gynecol. 2000;96:543–8.PubMedCrossRef
6.
Zurück zum Zitat Athawale R, Acharya N, Samal S, et al. Effect of mifepristone in cervical ripening for induction of labour. Int J Reprod Contracept Obstet Gynecol. 2013;2(1):35–8.CrossRef Athawale R, Acharya N, Samal S, et al. Effect of mifepristone in cervical ripening for induction of labour. Int J Reprod Contracept Obstet Gynecol. 2013;2(1):35–8.CrossRef
7.
Zurück zum Zitat Fathima S, Nayak SR, Rao B, et al. Mifepristone in induction of labour at term. Int J of Pham Biomed Res. 2013;4(3):164–6. Fathima S, Nayak SR, Rao B, et al. Mifepristone in induction of labour at term. Int J of Pham Biomed Res. 2013;4(3):164–6.
8.
Zurück zum Zitat Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labour induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol. 1992;80:972–5.PubMed Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labour induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol. 1992;80:972–5.PubMed
Metadaten
Titel
Safety and Efficacy of Oral Mifepristone in Pre-induction Cervical Ripening and Induction of Labour in Prolonged Pregnancy
verfasst von
Kanan Yelikar
Sonali Deshpande
Rinku Deshpande
Dipak Lone
Publikationsdatum
01.07.2015
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 4/2015
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-014-0584-6

Weitere Artikel der Ausgabe 4/2015

The Journal of Obstetrics and Gynecology of India 4/2015 Zur Ausgabe

Instrumentation and Techniques

Customized Silicone Vaginal Stent

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.